Skip to main content

Table 2 Risk of poor COVID-19 clinical outcomes with different classes of antihypertensives

From: Comparison of renin–angiotensin–aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes

Comparision

Odds ratio (meta-analysis)

95% CI

Method of analysis

Number of studies included in the sub-meta-analysis

Forest plot

ACEI to ARBs

0.94

0.84–1.04

MH

16

Figure S1

ACEIs to BBs

0.85

0.73–0.99

MH

7

Figure S2

ACEIs to CCBs

0.91

0.67–1.23

RE

8

Figure S3

ACEIs to Thiazides

1.22

1.02–1.45

MH

6

Figure S4

ACEIs to all other antihypertensives

0.91

0.84–0.99

MH

16

Figure S5

ARBs to all other antihypertensives

0.98

0.83–1.17

RE

16

Figure S6

ARBs to BBs

0.72

0.55–0.94

RE

7

Figure S7

ARBs to CCBs

0.90

0.62–1.33

RE

8

Figure S8

ARBs to Thiazides

1.15

0.97–1.37

MH

6

Figure S9

ARBs to all other non-RAAS antihypertensives

0.89

0.71–1.12

RE

11

Figure S10

ACEIs to all other non-RAAS antihypertensives

0.89

0.74–1.06

RE

11

Figure S11

CCBs to ACEI, ARBs, BBs

0.95

0.68–1.33

RE

10

Figure S12

ACEI, ARBs, BBs to CCBs and thiazides

1.13

0.87–1.47

RE

10

Figure S13

  1. Abbreviations: ACEI angiotensin-I-converting enzyme inhibitors, ARBs angiotensin II receptor blockers, BBs Beta blockers, CCBs calcium channel blockers, MH Mantel-Haenszel, RE random-effects. Figures S1-S13 are found in the supplementary file